Get the Stockscreener App
1.19
6.25%
0.07
Allogene Therapeutics Inc stock is traded at $1.19, with a volume of 7.28M.
It is up +6.25% in the last 24 hours and down -16.20% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
7.28M
Relative Volume:
1.99
Market Cap:
$264.04M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5613
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
+8.18%
1M Performance:
-16.20%
6M Performance:
-45.16%
1Y Performance:
-54.05%
1-Day Range:
$1.11
$1.23
1-Week Range:
$1.03
$1.23
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.19 | 241.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Q2 Cash Tops $300 Million - AOL.com
Allogene Therapeutics Inc. Facing Inflection Point in Trend AnalysisPrice Action & Daily Entry Point Alerts - beatles.ru
Real time pattern detection on Allogene Therapeutics Inc. stockJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
Ranking Allogene Therapeutics Inc. among high performing stocks via toolsTrade Volume Summary & Weekly Top Gainers Alerts - Newser
Will Allogene Therapeutics Inc. outperform the marketJuly 2025 Spike Watch & Reliable Price Action Trade Plans - Newser
Full technical analysis of Allogene Therapeutics Inc. stockWeekly Gains Summary & Safe Capital Allocation Plans - Newser
How to track smart money flows in Allogene Therapeutics Inc.Portfolio Profit Report & Community Supported Trade Ideas - Newser
What machine learning models say about Allogene Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - Newser
Backtesting results for Allogene Therapeutics Inc. trading strategiesBreakout Watch & Advanced Swing Trade Entry Plans - Newser
What recovery options are there for Allogene Therapeutics Inc.Weekly Market Summary & Safe Capital Allocation Plans - Newser
Published on: 2025-08-19 03:10:25 - Newser
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript - MSN
Can swing trading help recover from Allogene Therapeutics Inc. losses2025 Macro Impact & Low Risk Entry Point Tips - Newser
Signal strength of Allogene Therapeutics Inc. stock in tech scannersJuly 2025 Chart Watch & Safe Entry Point Identification - Newser
Will Allogene Therapeutics Inc. benefit from macro trendsJuly 2025 Levels & Weekly High Momentum Picks - Newser
Allogene Therapeutics Inc. stock chart pattern explainedBuy Signal & Breakout Confirmation Trade Signals - Newser
Understanding Allogene Therapeutics Inc.’s price movementTrade Analysis Report & Verified Swing Trading Watchlist - Newser
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges - TipRanks
Allogene Therapeutics Q2 2025 Earnings Preview: Revenue Expectations Flat, Earnings Estimates Rise - AInvest
Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - 富途牛牛
Allogene's Q2 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Allogene Therapeutics shares rise 1.92% premarket after reporting better-than-expected Q2 earnings. - AInvest
Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances - MSN
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline By Investing.com - Investing.com South Africa
Allogene Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Allogene Therapeutics Advances in CAR T Cell Therapy - TipRanks
ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest
Allogene Therapeutics Q2 2025 Earnings: A Strategic Leap in Cell Therapy Commercialization - AInvest
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Narrows Loss in Fiscal Q2 - Nasdaq
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan
Allogene Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Allogene Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):